BridgeBio Pharma ROE 2018-2024 | BBIO
Current and historical return on equity (ROE) values for BridgeBio Pharma (BBIO) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
| BridgeBio Pharma ROE - Return on Equity Historical Data |
| Date |
TTM Net Income |
Shareholder's Equity |
Return on Equity |
| 2024-09-30 |
$-0.44B |
$-1.22B |
37.43% |
| 2024-06-30 |
$-0.45B |
$-1.08B |
38.91% |
| 2024-03-31 |
$-0.54B |
$-1.04B |
43.70% |
| 2023-12-31 |
$-0.64B |
$-1.34B |
50.42% |
| 2023-09-30 |
$-0.61B |
$-1.20B |
49.03% |
| 2023-06-30 |
$-0.57B |
$-1.35B |
46.45% |
| 2023-03-31 |
$-0.43B |
$-1.21B |
36.97% |
| 2022-12-31 |
$-0.48B |
$-1.24B |
43.47% |
| 2022-09-30 |
$-0.49B |
$-1.13B |
48.40% |
| 2022-06-30 |
$-0.51B |
$-1.01B |
55.61% |
| 2022-03-31 |
$-0.60B |
$-1.04B |
76.68% |
| 2021-12-31 |
$-0.56B |
$-0.87B |
91.68% |
| 2021-09-30 |
$-0.54B |
$-0.74B |
144.69% |
| 2021-06-30 |
$-0.50B |
$-0.46B |
377.86% |
| 2021-03-31 |
$-0.52B |
$-0.39B |
-803.09% |
| 2020-12-31 |
$-0.45B |
$0.11B |
-163.72% |
| 2020-09-30 |
$-0.40B |
$0.22B |
-109.76% |
| 2020-06-30 |
$-0.35B |
$0.33B |
-78.15% |
| 2020-03-31 |
$-0.29B |
$0.45B |
-80.55% |
| 2019-12-31 |
$-0.26B |
$0.47B |
-104.42% |
| 2019-06-30 |
$-0.16B |
$0.00B |
inf% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$4.260B |
$0.009B |
|
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
|
